title: A nonpeptide vasopressin V(1a) receptor antagonist, SR 49059, does not prevent cisplatin-induced emesis in piglets.
abstract: We determined the pharmacological and the antiemetic properties of SR 49059, a selective nonpeptide V(1a) receptor antagonist, on cisplatin-induced emesis in the piglet. Firstly, we clearly demonstrate that SR 49059 is a potent V(1a) receptor antagonist in vitro and in vivo in the piglet. In binding studies, [3H]-SR 49059 exhibited high affinity for V(1a) receptors in piglet liver membranes (K(d) of 0.76 +/- 0.12 nM and B(max) of 138 +/- 22 fmol/mg prot.). In vivo, in decerebrate piglets, SR 49059 (1 mg/kg iv) antagonized AVP (500 ng/kg iv)-induced hypertension for at least 150 min and also blocked, for at least 270 min at 3 mg/kg iv, the pressor responses to exogenous LVP. After single and repeated iv or icv administration, we studied the antiemetic properties of SR 49059 on cisplatin-induced emesis in piglets. Animals receiving an emetic dose of cisplatin (5.5 mg/kg, iv) were observed continuously for 60 h. Piglets acting as controls were iv administered with vehicle 15 min prior to cisplatin infusion (T0(-15min)), while experimental animals received a single iv administration of SR 49059 at the dose of 1 or 3 mg/kg. In additional piglets, we administered SR 49059 (3 mg/kg) every 12 h from T0(-15min) to T48(-15min) (cumulative dose, 15 mg/kg). Another set of animals - observed only during the acute phase - was administered with SR 49059 (10 mg/kg) every 3 h from T0(-15min) to T15(-15min) (cumulative dose, 60 mg/kg). Lastly, 10 piglets were given a bilateral icv injection of SR 49059 (500 microg and 1500 microg/side) 1 h prior to cisplatin infusion. In all groups treated with SR 49059, the latency of the first emetic episode and the incidence of vomiting during the acute, the delayed and the cumulative phases remained statistically similar to that observed in controls, suggesting that V(1a) receptors are not involved in the onset and completion of nausea and vomiting.
authors.affiliation: Laboratoire de Physiologie des Relations Somato-Végétatives, Université de la Méditerranée, Faculté des Sciences du Sport, Case postale 910, 163 avenue de Luminy, 13288 Marseille cedex 09, France.
authors.forename: L
authors.initials: L
authors.lastname: Grélot
authors.forename: V
authors.initials: V
authors.lastname: Girod
authors.forename: J
authors.initials: J
authors.lastname: Dapzol
authors.forename: J P
authors.initials: JP
authors.lastname: Maffrand
authors.forename: C
authors.initials: C
authors.lastname: Serradeil-Le Gal
mesh_terms: D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D000932:Antiemetics / Q000494:pharmacology* / Q000627:therapeutic use; D000970:Antineoplastic Agents; D001127:Arginine Vasopressin / Q000502:physiology; D002462:Cell Membrane; D002945:Cisplatin; D004195:Disease Models, Animal; D006727:Hormone Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D006973:Hypertension / Q000139:chemically induced; D007211:Indoles / Q000494:pharmacology* / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects; D011759:Pyrrolidines / Q000494:pharmacology* / Q000627:therapeutic use; D013552:Swine; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D000932:Antiemetics; D000970:Antineoplastic Agents; D006727:Hormone Antagonists; D007211:Indoles; D011759:Pyrrolidines; D001127:Arginine Vasopressin; C082134:relcovaptan; D002945:Cisplatin